The mechanism of apatinib combined with neoadjuvant chemotherapy in the treatment of advanced ovarian cancer
LI Qian
TANG Xia
XIE Xinxian
Abstract：Objective To investigate the mechanism of apatinib combined with neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.Methods A total of 90 patients with advanced ovarian cancer who were admitted in Zhangjiakou First Hospital from April 2018 to April 2020 were enrolled in the study.Patients were divided into the control group(n=45,taxol and cisplatin regimen)and study group(n=45,apatinib plus taxol and cisplatin regimen)according to the treatment regimen.After chemotherapy,a cytoreductive surgery was performed in both groups.Microvessel density(MVD),positive rate of vascular endothelial growth factor(VEGF),apoptosis,key protein levels in the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin(PI3K/Akt/mTOR)signaling pathway,T lymphocyte subsets in peripheral blood and quality of life before and after treatment in two groups were analyzed.Results There were no significant differences in the MVD,positive rates of VEGF and VEGF receptor 2(VEGFR2),protein expressions of Bax,Cleaved Caspase-3,Bcl-2,p-PI3K,p-AKT and p-mTOR in ovarian cancer tissues,peripheral CD3+,CD4+,CD8+and CD4+/CD8+,and scores of social status,functional status,physiological status,emotional status,additional concern and other items before the treatment between the two groups(P＞0.05).After three courses,MVD,positive rates of VEGF and VEGFR2,protein expressions of Bcl-2,p-PI3K,p-AKT and p-mTOR in ovarian cancer tissues,peripheral blood CD8+,and scores of physiological status,emotional status,additional concern and other items were significantly reduced,while the protein expressions of Bax and Cleaved Caspase-3 in ovarian cancer tissues,peripheral blood CD3+,CD4+,and CD4+/CD8+,and scores of social status and functional status were significantly elevated in both groups(P＜0.05),which were more pronounced in the study group than the control group(P＜0.05).Conclusion Apatinib combined with neoadjuvant chemotherapy can effectively reduce the angiogenesis of tumor tissue,promote the apoptosis of ovarian cancer cells by suppressing the PI3K/Akt/mTOR signaling pathway,which improves the immune function and life quality of patients.
Keywords：apatinibneoadjuvant chemotherapyadvanced ovarian cancer
Publication Date：2025-06-26
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 939-942 )